Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 12/20 | 0.57 |
| ▸ | PGR | P06401 | 11/20 | 0.49 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.49 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.47 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SHBG | P04278 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7706417 | 0.88 | AR (0.71) | ARPGRNR3C2SERPINA6SLC22A1 | |
| SCHEMBL6836638 | 0.88 | AR (0.71) | ARPGRNR3C2SERPINA6SLC22A1 | |
| SCHEMBL18767879 | 0.88 | AR (0.52) | ARPGRNR3C2SERPINA6SLC22A1 | |
| SCHEMBL25863909 | 0.84 | AR (0.78) | ARPGRNR3C2SERPINA6SLC22A1 | |
| SCHEMBL25863905 | 0.84 | AR (0.78) | ARPGRNR3C2SERPINA6SLC22A1 | |
| SCHEMBL25863841 | 0.84 | AR (0.78) | ARPGRNR3C2SERPINA6SLC22A1 | |
| SCHEMBL25863878 | 0.84 | AR (0.78) | ARPGRNR3C2SERPINA6SLC22A1 | |
| SCHEMBL12884315 | 0.84 | AR (0.78) | ARPGRNR3C2SERPINA6SLC22A1 | |
| SCHEMBL25863881 | 0.84 | AR (0.78) | ARPGRNR3C2SERPINA6SLC22A1 | |
| SCHEMBL6836735 | 0.83 | LMNA (0.57) | ARPGRNR3C2SERPINA6SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105934-A1 | FULVESTRANT INTERMEDIATE | SYNTHON BV (NL) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105934-A1 | FULVESTRANT INTERMEDIATE | CYP19A1, NR5A1, HSD17B11 | AR 4/4885PGR 11/4885NR3C2 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.